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Aptamer-mediated survivin RNAi 
enables 5-fluorouracil to eliminate 
colorectal cancer stem cells
Hadi AlShamaileh1, Tao Wang1,2, Dongxi Xiang1, Wang Yin1, Phuong Ha-Lien Tran1, Roberto 
A. Barrero  3, Pei-Zhuo Zhang4, Yong Li5, Lingxue Kong6, Ke Liu7, Shu-Feng Zhou8, Yingchun 
Hou9, Sarah Shigdar1 & Wei Duan1
The development of chemoresistance and inability in elimination of cancer stem cells are among the 
key limitations of cancer chemotherapy. Novel molecular therapeutic strategies able to overcome 
such limitations are urgently needed for future effective management of cancer. In this report, we 
show that EpCAM-aptamer-guided survivin RNAi effectively downregulated survivin both in colorectal 
cancer cells in vitro and in a mouse xenograft model for colorectal cancer. When combined with the 
conventional chemotherapeutic agents, the aptamer-guided survivin RNAi was able to enhance the 
sensitivity towards 5-FU or oxaliplatin in colorectal cancer stem cells, increase apoptosis, inhibit tumour 
growth and improve the overall survival of mice bearing xenograft colorectal cancer. Our results indicate 
that survivin is one of the key players responsible for the innate chemoresistance of colorectal cancer 
stem cells. Thus, aptamer-mediated targeting of survivin in cancer stem cells in combination with 
chemotherapeutic drugs constitutes a new avenue to improve treatment outcome in oncologic clinics.
Cancer stem cells are regarded as the ‘roots of cancer’ and therefore are an attractive therapeutic target to inhibit 
tumour growth, expansion and metastasis1, 2. Current approaches in treating cancer patients include surgical 
resection with chemotherapy or radiotherapy. Although they are effective in eliminating the majority of the can-
cer cells, their inability to eliminate the cancer stem cell population remains a limitation for current regimen for 
cancer treatment3–7. Indeed, cancer stem cells have been shown to be resistant to conventional anticancer drugs 
through a variety of mechanisms including overexpression of ABC transporters, active DNA-repair capacity, 
overexpression of antiapoptotic proteins, and elevated autophagy8–10.
5-fluorouracil (5-FU) is a chemotherapeutic drug widely used for the treatment of colorectal cancer and is 
often included in the first line treatment. However, cancer stem cells in colorectal cancer have been shown to 
be resistant to 5-FU as well as other chemotherapeutic drugs such as oxaliplatin and irinotecan11. Furthermore, 
the use of these drugs could lead to the enrichment of cancer stem cells with high tumourigenic capacities in 
a number of solid cancers11–13. Thus, despite the efficacy of these drugs against bulk cancer cells, they remain 
mostly ineffective against cancer stem cells14, 15. We hypothesized that aptamer-mediated survivin RNAi enables 
5-fluorouracil to eliminate colorectal cancer stem cells and improves the survival of the mice bearing xenograft 
tumour.
Aptamers are single stranded DNA or RNA that fold into defined 3-D structure and bind to their targets spe-
cifically. As ‘chemical antibodies’, aptamers offer significant advantages over antibodies in terms of smaller size, 
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lower immunogenicity, increased stability, ease of synthesis and modification16–19. As a targeting module, aptam-
ers allow for improved delivery of drugs to tumour cells while minimizing the side effects often associated with 
the drugs. Our laboratory has developed the first RNA aptamers that target the cancer stem cell markers EpCAM. 
Upon binding to target cells, our EpCAM aptamers undergo receptor-mediated endocytosis which allows for con-
trolled release of drugs intracellularly20, 21. Here we describe the use of the EpCAM aptamer in delivering siRNA 
to target survivin expression in order to eliminate colorectal cancer stem cells.
Survivin, a member of inhibitors of apoptosis proteins family, is an attractive target for anticancer therapies 
for its role in inhibiting apoptosis and its close association with stem cells22, 23. In addition to its critical role in 
inhibiting cell death, survivin is expressed at low levels or absent in terminally differentiated healthy cells, but its 
expression is significantly elevated in human tumours and its overexpression is further enhanced when exposed 
to traditional anticancer treatments24–26. However, the role of survivin in the development of chemoresistence in 
solid tumours remains largely unexplored. Here we demonstrate that by silencing survivin expression in colorec-
tal cancer stem cells using an aptamer-siRNA chimera, the innate chemoresistance to traditional chemothera-
peutic agents in colorectal cancer stem cells was reversed, transforming an old anticancer drug into a cancer stem 
cell killer.
Results
Effective downregulation of survivin via EpCAM Aptamer-guided RNAi in colorectal cancer 
cells. In this study, we targeted survivin expression in colorectal cancer stem cells using a chimeric structure 
composed of an EpCAM-specific RNA aptamer as the binding moiety and a survivin siRNA sequence (Supp. 
Fig. 1). The efficacy of EpCAM aptamer-survivin siRNA chimera in the downregulation of survivin was initially 
tested on EpCAM-positive colorectal cancer cell line HT-29 with the EpCAM-negative cell line HEK-293T and 
a survivin RNAi-deficient variant chimera as negative controls (Supp. Fig. 1)27. Both cell lines were treated with 
20 nM of the chimera or the negative control chimera for 24 hours or 48 hours in the absence of any transfection 
agent and subjected to qRT-PCR and Western analysis, respectively. As shown in Fig. 1a,d,e, the treatment of 
chimera resulted to a ~70% knockdown of both survivin mRNA and protein levels in EpCAM-positive HT29 
cells but not in the EpCAM-negative control HEK293T cells. Having demonstrated the efficacy and selectivity of 
EpCAM-directed survivin RNAi in vitro, we proceeded to evaluate the chimera-mediated survivin RNAi in vivo. 
To this end, a 20-kDa polyethylene glycol (PEG) was attached to the chimera to increase circulatory half-life of 
the chimera in mice (Supp. Fig. 1)27.
Next, we studied efficacy and mode of action of aptamer-guided survivin RNAi in vivo. The HT29 xeno-
graft tumour-bearing NOD/SCID mice were treated with a single dose of 2 nmol/mouse of the PEG-chimera 
i.v. Forty-eight hours after the treatment, the tumours were removed and the survivin mRNA content in the 
treated HT29 xenograft tumour was evaluated. As shown in Fig. 1b, a single dose of 2 nmol/mouse of the chimera 
resulted in the reduction of survivin mRNA in the xenograft tumour by ~40%. Furthermore, a 5′RACE assay on 
the RNA extracted from the treated xenograft tumour suggests specific survivin mRNA cleavage at the expected 
siRNA cut site through the Argonaute2 (Ago2) mechanism (Fig. 1c). Taken together, these data indicate that 
aptamer-siRNA chimera is able to effectively downregulate survivin in EpCAM-positive colorectal cancer cells 
both in vitro and in vivo in the absence of transfection reagent.
Survivin silencing combined with 5-FU target colorectal cancer stem cells in vitro. Next, we 
explored if the downregulation of survivin would lead to the increased sensitivity of colorectal cancer stem cells 
to standard chemotherapy agents, such as 5-FU, in vitro and in vivo. For the evaluation of the elimination of 
colorectal cancer stem cells rather than the bulk cancer cells, we used self-renewal and tumour-formation as the 
key experimental endpoints as such properties reflect the defining functional characteristics of the cancer stem 
cell population28–30.
For an in vitro assessment of the self-renewal capacity of cancer stem cells, HT-29 cells were treated with the 
EpCAM aptamer-survivin siRNA chimera or negative control chimera, followed by further incubation in the 
presence or absence of 2 µM 5-FU for 5 days. A tumoursphere formation assay was used to enumerate the num-
ber of tumourspheres formed. As shown in Fig. 2 and Suppl. Fig. 2, a statistically significant 3-fold decrease in 
self-renewal was observed when HT-29 cells were treated with combined survivin chimera and 5-FU. In contrast, 
the treatment with either chimera or 5-FU alone, negative control chimera or saline did not lead to significant 
decrease in self-renewal capacity of the HT-29 cells in vitro. These data indicate that only the combinatorial 
treatment of survivin knockdown and 5-FU but not the mono-treatment regimen or the negative controls, effec-
tively impaired the self-renewal capacity of HT-29 in vitro. To further verify if the combinatorial treatment leads 
to the impairment of tumourigenicity of colorectal cancer stem cells in vivo, we performed tumour xenograft 
experiments under the limiting dilution conditions. Treated HT-29 cells were implanted subcutaneously into 
the immunodeficient NOD/SCID mice at limiting dilutions with an inoculation cell dose between 1 × 103 to 
5 × 104 cells per mouse. As shown in Table S1, there was no significant decrease in tumourigenicity poten-
tial in HT-29 cells treated with 5-FU alone or with the negative control chimera. Similarly, targeting survivin 
expression by mono-treatment with the chimera had little impact on the tumour-forming potential compared 
to that of saline-treated control (Table S1). In contrast, a significant decrease in HT-29 tumour formation for 
HT-29 cells treated with the combinatorial regimen was evident, indicating that although survivin knockdown 
as a mono-treatment is not sufficient to eliminate HT-29 cancer stem cells, the combination with survivin RNAi 
with classical chemotherapeutic drugs, such as 5-FU, is able to eliminate colorectal cancer stem cells. The down-
regulation of survivin in empowering traditional chemotherapeutic agents to eliminate colorectal cancer stem 
cell is not limited to 5-FU as the combined treatment with aptamer-survivin siRNA chimera and oxaliplatin had 
a similar efficacy in the impairment of self-reviewal capacity of HT-29 colorectal cancer stem cells (Supp. Fig. 3).
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Combinatorial survivin knockdown and 5-FU treatment in vivo eliminates colorectal can-
cer stem cells. To evaluate if the combinatorial treatment of chimera and 5-FU leads to the elimina-
tion of HT-29 cancer stem cells in vivo, we treated HT-29 xenograft tumour-bearing NOD/SCID mice using 
PEG-aptamer-siRNA chimera with or without 5-FU. Mice bearing 60 mm3 HT-29 tumours received i.v. injections 
of aptamer-siRNA chimera (2 nmol/mouse) on days 1, 3, and 5 with or without 30 mg/kg of 5-FU injections on 
days 3, 5, and 7. Forty-eight hours after the last treatment, tumours were removed (Supp. Fig. 4) and single-cell 
suspensions were subjected to tumoursphere formation assay to analyze their self-renewal capacities. As shown 
in Table 1 and Supp. Fig. 5, xenograft tumours from mice that received chimera in the absence of 5-FU showed 
no significant change in self-renewal when compared with saline-treated mice. Similarly, 5-FU alone or control 
chimera had no significant impact on self-renewal either. Interestingly, the HT29 xenograft tumours from the 
mice that received aptamer-survivin siRNA chimera in combination with 5-FU showed significant reduction in 
self-renewal (Table 1).
As 5-FU is known to kill cancer cells via the induction of apoptosis, we proceeded to investigate the mecha-
nism of action in colorectal cancer stem cells upon combinatorial treatment of chimera and 5-FU in vivo. For this 
purpose, dissociated tumour cells and tumour sections from mice were fixed and underwent TUNEL staining 
to enumerate apoptotic cells (Fig. 3 and Supp. Fig. 6). Tumours from mice that received mono-treatments of 
Figure 1. EpCAM aptamer-guided RNAi effectively silenced survivin. (a) Specificity and efficacy of EpCAM-
aptamer guided RNAi in knocking down survivin mRNA. Chimera or negative control chimera were incubated 
with HT-29 or HEK-2913T cells for 24 hours and the total RNA was extracted for qRT-PCR analysis of survivin 
mRNA levels. GAPDH was used as an internal control. (b,c) HT-29 Tumour-bearing mice were treated with 2 
nmol/mouse of PEG-labelled chimera for 48 hours. The tumours were collected for RNA extraction followed 
by qRT-PCR analysis of survivin mRNA expression (b) and 5′RACE assay (c). (d) Effective downregulation 
of survivin protein via EpCAM aptamer-guided RNAi. Chimera or negative control chimera were incubated 
with HT-29 or HEK-2913T cells for 48 hours and the survivin protein levels were analyzed using Western blot 
analysis. β-actin was used as a loading control. (e) The bar graph shows the survivin protein levels in various 
treatment groups. Data shown are means ± SEM, n = 3. *p < 0.05, **p < 0.005. NS, no statistically significant 
difference.
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chimera or 5-FU were found to have 7.23% ± 2.038 and 9.132% ± 0.5787 apoptotic cells, respectively (Fig. 3a,b). 
Similarly, tumours from mice that received negative control chimera with 5-FU treatment showed 3.975% ± 3.213 
of the population to have undergone apoptosis. In contrast, tumours from mice that received combinatorial treat-
ment of chimera and 5-FU displayed enhanced apoptosis as 20.88% ± 3.32 of the tumour cell population had 
undergone apoptosis. Thus, EpCAM aptamer-guided RNAi of survivin enhanced the 5-FU-mediated cell death 
in colorectal cancer cells via enhanced apoptosis. Furthermore, tumour sections stained for Ki-67 demonstrated 
4-fold decrease of tumour cell proliferation when treated with chimera and 5-FU combinatorial treatment (Supp. 
Fig. 7).
EpCAM-aptamer guided in vivo survivin RNAi enhanced treatment efficacy of 5-FU. Next, we 
examined if the suppression of self-renewal and increased apoptosis conferred by the combinatorial treatment of 
aptamer-guided survivin siRNA and 5-FU in vivo would result in an improved treatment efficacy in mice bear-
ing HT-29 xenograft tumour. NOD/SCID mice bearing HT-29 xenograft colorectal tumours were treated with 
2 nmol/mouse of PEG-chimera or negative control chimera on days 1, 3, and 5, with or without 30 mg/kg 5-FU 
on days-3, 5, 7, 9, and 11. The changes in tumour volume were monitored daily until the animals reached their 
experimental endpoints. The mice that underwent mono-treatment with the chimera showed no signs of reduced 
rate of tumour growth (Fig. 4a) nor improvement in survival (Fig. 4b) when compared to the saline control group. 
The tumour-bearing mice that received 5-FU mono-treatment with or without the negative control chimera 
showed slower tumour growth compared to the saline group (Fig. 4a). In contrast, the combinatorial treatment 
of chimera and 5-FU led to the significantly slower rate of tumour growth compared to the mice that received 
5-FU treatment with or without negative control chimera (Fig. 4a), and improved overall survival within the first 
month of treatment (Fig. 4b).
Figure 2. EpCAM aptamer mediated survivin knockdown transforms 5-FU into a colorectal cancer stem 
cell killer. Colorectal cancer HT-29 cells were first treated with EpCAM aptamer-survivin siRNA chimera for 
24 hours followed by treatment with 2 μM 5-FU for 5 days. Tumoursphere formation assay was used to examine 
the self-renewal capacities of treated cells. The bar graph shows the estimated stem cell frequencies. Data shown 
are means ± SEM, n = 3. ***p < 0.001. NS, no statistically significant difference.
Treatment group
Number of cells/well Estimated stem 
cell frequency
95% confidence 
interval50 20 10 5 1
Saline 4/10 3/10 1/10 1/10 0/10 1.3% 0.65–2.5%
Saline + 5-FU 5/10 1/10 1/10 0/10 0/10 0.99% 0.47–2.1%
Neg. chimera control + 5-FU 3/9 1/7 1/10 0/10 0/10 0.76% 0.32–1.8%
Chimera 3/7 1/10 1/10 0/10 0/10 0.81% 0.30–1.9%
Chimera + 5-FU 1/10 1/10 0/10 0/10 0/10 0.24% 0.06–0.97%
Table 1. Elimination of cancer stem cells via combined in vivo survivin knockdown and 5-FU treatment in vivo.
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Discussion
Survivin is known to be overexpressed after chemotherapy and radiotherapy in many solid cancers including 
colorectal cancer, and such overexpression is largely associated with drug resistance, tumour aggressiveness and 
poor prognosis31. Our experience with chemotherapeutic drugs in the past 60 years indicates that despite the 
limited success in eliminating the bulk cancer cells, these anti-cancer agents, such as 5-FU, remain largely inef-
fective against cancer stem cells14, 15. Here we describe the use of an oligonucleotide chimera made up of an 
EpCAM-specific aptamer and a survivin siRNA to downregulate survivin in both the bulk and colorectal cancer 
stem cells without the aid of transfection agent or other delivery vehicles such as viral vectors or nanodrug carri-
ers. When combined with the co-treatment with conventional chemotherapy drugs, the aptamer-guided survivin 
RNAi resulted in enhanced sensitivity of the cancer stem cells towards 5-FU or oxaliplatin. The aptamer-siRNA 
chimera used here was previously established to specifically target EpCAM-expressing cancer cells, undergo 
receptor-mediated endocytosis upon binding to target cells, and engage cell’s endogenous RNAi machinery27. 
Notably, EpCAM is overexpressed on both bulk cancer cells and cancer stem cells32, 33. We purposely engineered 
an EpCAM aptamer with a moderate dissociation constant so that it will preferentially be enriched at the site of 
tumour as cancer cells express up to 1000-fold higher EpCAM than normal epithelial cells34, 35. Therefore, the 
EpCAM aptamer-survivin siRNA chimera used in this study can effectively target both the cancer stem cells and 
non-cancer stem cells in vivo. Such dual targeting capacity is critical for the success of clinical oncology since it 
has been established that cancer stem cells and non-cancer stem cell may interconvert, and survivin has been 
shown to be involved in the regulation of such interconversion36, 37. It is thus imperative not to limit the targeted 
therapies against cancer stem cells but also target the non-cancer stem cell population simultaneously. To our 
knowledge, this fully synthetic aptamer-siRNA chimera is the shortest of its kind ever developed, providing rela-
tive ease for large scale chemical synthesis and modification27.
Figure 3. Survivin knockdown in vivo enhances 5-FU-induced apoptosis in HT-29 tumour cells. (a) 
Representative images of TUNEL apoptosis assay on dissociated HT-29 xenograft tumours after in vivo 
treatment with chimera and 5-FU. NOD/SCID mice bearing HT-29 tumours (60 mm3) were treated 
intravenously with 3 injections of 2 nmol/mouse of chimera with or without 3 additional treatment of 30 mg/
kg of 5-FU. Two days after the final treatment, tumours were dissociated by collagenase digestion and subjected 
to TUNEL apoptosis assay. (b) Percentage of apoptotic cells in treated tumours. Data shown are means ± SEM, 
n = 3. ****p < 0.001. NS, no statistically significant difference.
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Depending on the experimental systems and approaches used, inhibition of survivin function alone could lead 
to decreased tumour cell viability, increased apoptosis, or inhibition of tumour growth38, 39. It could also lead to no 
detectable changes in cell viability, stemness or tumour growth as found in our studies and by others27, 40. Indeed, 
clinical trials with survivin inhibition have revealed that the anti-cancer efficacy of the inhibition of survivin is 
more pronounced when combined with chemotherapy41–44. This is in agreement with our finding that survivin 
silencing with the chimera was only effective against cancer stem cells when combined with 5-FU, resulting in 
reduced self-renewal and tumour growth and enhanced apoptosis (Figs 2–4). Therefore, our data suggest that 
survivin is one of the key players responsible for the innate chemoresistance of colorectal cancer stem cells. Taken 
together, our results indicate that targeting survivin in cancer stem cells in combination with chemotherapeutic 
drugs constitutes a new avenue to improve treatment outcome in oncologic clinics.
Chemotherapy is one of the important treatment strategies used for managing patients with cancer. For 
colorectal cancer, 5-FU and oxaliplatin are the major chemotherapeutic agents used by oncologists for treating 
colorectal cancer. Such drugs are known to be largely ineffective in killing cancer stem cells. Furthermore, innate 
chemoresistance is responsible for the drug-resistance frequently encountered in colorectal cancer patients. Our 
data presented here suggest that downregulation of survivin results in the reversal of the innate chemoresistance 
to both 5-FU and oxaliplatin in colorectal cancer stem cells (Figs 2, 3 and 4, Table 1). By combining targeted 
siRNA delivery with the treatment of 5-FU, we have transformed a standard chemotherapeutic drug known to be 
ineffective against cancer stem cells into an effective colorectal cancer stem cell killer. In addition to in vitro and 
ex vivo data which showed promising results for the combinatorial treatment of chimera and 5-FU in enhancing 
apoptosis and eliminating cancer stem cells, in vivo treatment of tumour-bearing mice using PEG-labeled chi-
mera with 5-FU via tail vein injection resulted in enhanced tumour apoptosis and reduced tumour self-renewal 
(Figs 3 and 4). As shown in Fig. 4, the most prominent effect of the combinatorial treatment of aptamer-guided 
survivin siRNA and 5-FU occurred within the first 25 days of treatment. The limited number of chimera injec-
tions may have been insufficient in maintaining survivin downregulation in the HT-29 tumours throughout the 
duration of the combinatorial treatment. Additionally, the continuation of 5-FU treatments without the chi-
mera potentially elicited pro-survival responses such as autophagy, contributing to drug resistance and tumour 
growth45–47. Thus, our results suggest that maintaining survivin downregulation simultaneously with chemother-
apy may be required in order to enhance the anti-tumour efficacy and improved outcome in oncologic clinics.
In conclusion, EpCAM aptamer-guided delivery of survivin siRNA is able to target both the bulk and cancer 
stem cells in a xenograft colorectal cancer model. The aptamer-guided knockdown of survivin reverses the innate 
chemoresistance of colorectal cancer stem cells. The aptamer-mediated siRNA delivery to cancer stem cells in vivo 
opens a new avenue to target specific cancer cell populations and to modulate genes that are critical for cancer cell 
survival and chemoresistance.
Figure 4. Combined chimera and 5-FU treatments improves therapeutic outcome in HT-29 tumour-bearing 
mice. (a) The graph represents the tumour volume in mice in response to various treatments as indicated. (b) 
Survival rate of mice observed over the course of various treatments. Data shown are mean ± SEM, n = 4–5.
www.nature.com/scientificreports/
7Scientific RepoRts | 7: 5898  | DOI:10.1038/s41598-017-05859-z
Material and Methods
Animals. Female 6-week old immunodeficient NOD/SCID mice were purchased from the Animal Resources 
Centre (Perth, Australia). All experiments were performed in accordance with the Australian Code of Practice 
for the Care and Use of Animals for Scientific Purposes and Guidelines to Promote the Wellbeing of Animals 
Used for Scientific Purposes from Australian Government’s National Health and Medical Research Council. The 
Deakin University Animal Ethics Committee approved all experimental protocols.
Cell culture. HT-29 (human colorectal adenocarcinoma, ATCC® HTB38™) cells were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen, Australia) supplemented with 10% fetal bovine serum 
(FBS, Hyclone, Canada), 50 U/L penicillin and streptomycin (Invitrogen, Australia) and 1× Glutamax (Life 
Technologies). Cell cultures were kept in a humidified atmosphere with 5% CO2 at 37 °C. For aptamer-siRNA 
treatment, 20 nM of either chimeras were added to the cell culture for 48 and 24 hours for total protein and RNA 
extraction, respectively.
Western analysis. Western analysis was performed as described in detail in our previous publication27. 
The primary antibodies used in the western blot were mouse anti-human β-actin (1:5000, Sigma) and mouse 
anti-human survivin (1:400, Cat. No: SC-17779, Santa Cruz). The secondary antibodies were HRP-conjugated 
goat anti-mouse secondary antibody (1:10000, Thermo Fisher) or goat anti-rabbit secondary antibody (1:5000, 
Pierce). Quantification of ECL signals was conducted using a LAS-4000 Imaging System (GE Healthcare Life 
Sciences) with β-actin as a loading control.
RNA extraction and qrRT-PCR. Total RNA was extracted using Trizol (Invitrogen) following the 
manufacturer’s protocol, and cDNA was generated from the extracted RNA using High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems). Fast SYBR Green Master Mix (Invitrogen) and Stratagene Mx3000 P system 
(Agilent Technologies) were used to carry out qRT-PCR assays with GAPDH as an internal control. The primers 
used for qRT-PCR assays were survivin (forward primer: 5′-GAACTGGCCCTTCTTGGAG-3′, reverse primer: 
5′-AAGTCTGGCTCGTTCTCAGT-3′) and GAPDH (forward primer: 5′-GAAATCCCATCACCATCTTCCAGG-3′, 
reverse primer: 5′-GAGCCCCAGCCTTCTCCATG-3′).
In vitro tumoursphere and ex vivo xenograft assays. The tumoursphere assay was performed in 
accordance with previously reported protocols48. Cells were collected by trypsinization and resuspended as single 
cells in cancer stem cell media containing serum-free DMEM/F12 (Invitrogen) supplemented with 100 units/mL 
B27 (Gibco), 10 µg/mL Insulin (Sigma), 20 ng/mL EGF (Sapphire Bioscience), and 20 ng/mL bFGF (Sapphire 
Bioscience). The cells were plated in a round-bottom 96-well ultra-low attachment plates (Corning) at densities 
of 1, 5, 20, and 50 cells/well. Sphere formation was recorded 5–7 days after incubation at 37 °C in a humidified 
atmosphere with 5% CO2. Cancer stem cell frequency was calculated using the limiting dilution software package 
(ELDA) on the website of Walter and Eliza Hall Institute of Medical Research (http://bioinf.wehi.edu.au/software/
elda/index.html)49. Only spheres with a size larger than 50 µm in diameter were counted. For ex vivo xenograft 
assay, cells were injected subcutaneously into the left flanks of female NOD/SCID mice at three cell densities (5 × 
104, 1 × 104, and 1 × 104) in serum-free DMEM with Matrigel at 1:1 ratio. Tumours were detected by palpation.
Mice treatment for in vivo tumoursphere and xenograft assays. Female NOD/SCID mice with 
HT-29 tumours (60 mm3) in the left flanks received 2 nmol of aptamer-siRNA chimera intravenously via the 
tail-vein on days 1, 3, and 5, and PBS on day 7, while mice with 5-FU treatment received PBS i.v. injection on day 
1 and 30 mg/kg of 5-FU via on days 3, 5, and 7. The tumours were collected 48 hours after the final injection and 
dissociated into single cell suspensions to be used for in vitro tumoursphere assay (50, 20, 10, 5, 1 cells/well) and 
xenograft assay (1 × 105, 1 × 104, 1 × 103, 1 × 102 cells/mouse). The cancer stem cells frequency was measured 
using the limiting dilution software package on the website of Walter and Eliza Hall Institute of Medical Research 
(http://bioinf.wehi.edu.au/software/elda/index.html)49.
Tumour dissociation. Tumours collected from xenografts were washed thoroughly with Hank’s buffer 
containing 1% penicillin/streptomycin to remove excess blood and any extraneous material. The tumours were 
placed in a sterile petri dish and minced into smaller pieces (approximately 2–4 mm3) with a scalpel. The chopped 
tissues were collected and rinsed with Hank’s buffer, then suspended in dissociation medium containing DMEM, 
20% FBS, 2% penicillin/streptomycin, 100 units/mL B27, 10 µg/mL Insulin, 20 ng/mL EGF, 20 ng/mL bFGF, and 
50 U/mL collagenase II (Sigma). The dissociation medium was used on the chopped tumours at a ratio of 6 ml per 
gram of tumour and incubated at 37 °C overnight on a rotating orbit mixer incubator. Cells were collected after 
incubation and centrifuged at 1,000 g for 5 minutes. The pellets were suspended and washed with PBS twice by 
centrifugation at 500 g to remove any residual debris.
TUNEL assay. The dissociated tumour cells were washed with PBS and fixed on glass slides with 1% par-
aformaldehyde. Apoptotic cells were detected using TUNEL Apoptosis Detection Kit (Millipore) follow-
ing the manufacture’s protocol. Fixed cells were counterstained with mounting medium (Vectashield, Vector 
Laboratories, Burlingame, CA) containing 1 µg/mL DAPI, and the cells were visualized with Fluoview FV10i laser 
scanning confocal microscope (Olympus, NSW, Australia).
In vivo treatment for tumour growth rate and survival. Female NOD/SCID mice with HT-29 tumours 
(60 mm3) in the left flanks received 2 nmol of aptamer-siRNA chimera on days 1, 3, and 5, and PBS on days 7, 9, 
and 11, while mice with 5-FU treatment received intravenous injection of PBS on day 1 and 30 mg/kg of 5-FU via 
IV injections on days 3, 5, 7, 9 and 11. The weights and tumour dimensions of mice were monitored daily. The 
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endpoints set for the experiments were defined by rapid weight loss by 20% of the body weight, tumour diameter 
exceeding 13 mm, and any health deteriorations impacting on the welfare of the animal as set by the Deakin 
University Animal Ethics Committee. Tumour diameters were measured with a digital caliper and tumour vol-
ume was calculated with the formula: Volume = Length × Width2/2.
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